Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04285411
Other study ID # PR 2019-353
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 4, 2019
Est. completion date November 20, 2019

Study information

Verified date May 2020
Source Vital USA, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Clinical Investigation Plan: Vital USA SpO2 Accuracy Comparison to Arterial Blood CO-Oximetry Study ID# PR 2019-353, Version: Rev 1, Date: 15 Oct 2019 Study Dates: November 4-5, 2019


Description:

An SpO2 accuracy comparison was conducted as part of the final validation of the VitalDetect™ pulse oximetry system. The study was conducted in accordance to Code of Federal Regulations (CFR) for Non-Significant Risk (NSR) investigational studies, following International Standards Organization (ISO) 14155:2011 as appropriate and the pulse oximetry guidelines of ISO 80601-2-61:2017 applicable sections, and Pulse Oximeters - Premarket Notifications Submissions [510(k)s] Guidance For Industry and Food and Drug Administration Staff (issued: March 4, 2013).

The purpose of this study was to validate the SpO2 accuracy of the VitalDetect™ pulse oximetry system during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. It was expected that the Accuracy Root Mean Square (ARMS) performance of the oximetry system would meet the required specification of ARMS of 3.0% or less.

A secondary goal was to evaluate the pulse rate performance simultaneously collected over the SpO2 range covered. The Pulse Rate Accuracy Root Mean Square (Arms) performance of the VitalDetect™ pulse oximetry system, were expected to meet a specification of 3 bpm.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date November 20, 2019
Est. primary completion date November 5, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 52 Years
Eligibility Inclusion Criteria

1. 10-15 Adults with a minimum of 3 males and a minimum of 3 females, with the balance made up of either

2. Subject must have the ability to understand and provide written informed consent

3. Subject is 18 to 50 years of age

4. Subject must be willing and able to comply with study procedures and duration

5. Subject is a non-smoker or who has not smoked within 2 days prior to the study

Exclusion Criteria

1. Subject is considered as being morbidly obese (defined as BMI >39.5).

2. Compromised circulation, injury, or physical malformation of fingers, wrist, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow subjects to participate if the condition is noted and would not affect the particular sites utilized.)

3. Female subjects that are actively trying to get pregnant or are pregnant (confirmed by positive urine pregnancy test unless the subject is known to be not of child-bearing potential).

4. Smoker Subjects who have refrained will be screened for COPD levels >3% as assessed with a Radical 7 (Rainbow)

5. Subjects with known respiratory conditions such as: (self-reported):

1. uncontrolled / severe asthma,

2. flu,

3. pneumonia / bronchitis,

4. shortness of breath / respiratory distress,

5. unresolved respiratory or lung surgery with continued indications of health issues,

6. emphysema, COPD, lung disease.

6. Subjects with known heart or cardiovascular conditions such as: (self-reported, except for blood pressure and ECG review)

1. hypertension: systolic >140mmHg, Diastolic >90mmHg on 3 consecutive readings (reviewed during health screen).

2. have had cardiovascular surgery

3. Chest pain (angina)

4. heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen)

5. previous heart attack

6. blocked artery

7. unexplained shortness of breath

8. congestive heart failure (CHF)

9. history of stroke

10. transient ischemic attack

11. carotid artery disease

12. myocardial ischemia

13. myocardial infarction

14. cardiomyopathy

7. Self-reported health conditions as identified in the Health Assessment Form (self-reported)

1. diabetes,

2. uncontrolled thyroid disease,

3. kidney disease / chronic renal impairment,

4. history of seizures (except childhood febrile seizures),

5. epilepsy,

6. history of unexplained syncope,

7. recent history of frequent migraine headaches,

8. recent symptomatic head injury (within the last 2 months)

9. cancer / chemotherapy

8. Subjects with known clotting disorders (self-reported)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Accuracy of the VitalDetect™ pulse oximetry system
The purpose of this study was to validate the SpO2 accuracy of the VitalDetect™ pulse oximetry system during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. It was expected that the Accuracy Root Mean Square (ARMS) performance of the oximetry system would meet the required specification of ARMS of 3.0% or less.

Locations

Country Name City State
United States Clinimark Laboratory Services Louisville Colorado

Sponsors (2)

Lead Sponsor Collaborator
Vital USA, Inc. Clinimark, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate SpO2 Accuracy Per Standards for Pulse Oximetry. This study was a comparative, single-center, non-randomized study conducted to evaluate the SpO2 accuracy per standards and guidelines identified above for SpO2 accuracy for pulse oximetry equipment over the range of 70-100% SaO2 under non-motion conditions. Arterial blood sampling measured by functional SaO2 CO-Oximetry, was used as the basis for comparison. As a secondary goal, the pulse rate accuracy was compared to ECG Heart Rate realized over the range throughout the hypoxia procedure. Testing was conducted under normal office environment conditions. 90 Seconds
Secondary The Pulse Rate Accuracy Compared to ECG Heart Rate. The pulse rate accuracy was compared to ECG Heart Rate as recorded by the S5 Multi-parameter monitor. Passing criteria was an ARMS of 3 bpm or better based measurements observed during the pulse oximetry evaluation. 90 Seconds
See also
  Status Clinical Trial Phase
Recruiting NCT04511234 - Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease N/A
Completed NCT04359446 - Laser-excimer Versus High-pressure Dilation to Treat Under-expansion of the Stent N/A
Recruiting NCT03478709 - Dynamic Arterial Elastance: an Indirect Marker of the Critical Capillary Pressure at the Microcirculatory Level
Not yet recruiting NCT05554055 - Correlation Between LR-ACT and Anti Xa Activity During Endovascular Surgery Procedures. AXAES (Anti Xa vs ACT-LR in Endovascular Surgery)
Completed NCT04651894 - Relationship Between Digital Vascular Function Measured by EndoPAT® in elderlY Patients and Arterial Stiffness
Active, not recruiting NCT04061798 - ACT Guided Heparinization During Open Abdominal Aortic Aneurysm Repair. Phase 4
Recruiting NCT04428138 - Inguinal Hernia and Arterial Disease
Withdrawn NCT01570803 - Efficacy Between Different Two Self-Expanding Nitinol Stents For The Atherosclerotic Femoro-Popliteal Arterial Disease N/A
Active, not recruiting NCT03970538 - PROMISE II: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia N/A
Recruiting NCT03426293 - Measuring the ACT During Non-cardiac Arterial Procedures.
Recruiting NCT04258046 - Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation Phase 2
Recruiting NCT05054764 - Promus PREMIER Below The Knee Registry